Blog
Long-form on GLP-1 peptides.
The deep dives — mechanisms, comparisons, and how to think clearly about a fast-moving class of medicines.
Retatrutide and Heart Outcomes: What We'll Know and When
Retatrutide has no cardiovascular outcomes trial yet. What SELECT and SURPASS-CVOT showed — and when retatrutide's CVOT readout is realistically expected.
Should I Wait for Retatrutide? How Doctors Are Counseling
Retatrutide's Phase 2 data looks compelling. But waiting for it means months or years of untreated obesity. Here's how doctors are framing the decision.
Tirzepatide and Bone Density: What We Know and Don't
Tirzepatide drives significant weight loss, but rapid loss can affect bone mineral density. Here's what SURMOUNT data shows and how to protect your bones.
Tirzepatide and Resistance Training: Protein and Lifting
Tirzepatide accelerates weight loss, but roughly 35-40% of what leaves is lean mass. Here's the body composition data, the protein math, and a practical lifting approach.
Why Eli Lilly Bet on Triple Agonism (and What Comes After)
Eli Lilly's retatrutide pipeline reflects a deliberate bet that more receptor targets mean more weight loss. Here's the strategic logic and what orforglipron adds.
Insurance and Retatrutide: What Coverage Will Likely Look Like
Retatrutide coverage will follow patterns set by Wegovy and Zepbound — prior auth, employer opt-outs, and Medicare rules. Here's what to expect and how to prepare.
The Tirzepatide 5 mg Sweet Spot: What the Data Shows
SURMOUNT-1 subgroup data shows some patients hit their goals at 5 mg tirzepatide and gain little from stepping up. Here's how to read the cost/side-effect curve.
Tirzepatide and HFpEF: What the SUMMIT Trial Means
The SUMMIT trial showed tirzepatide improved KCCQ scores and NYHA class in HFpEF patients with obesity. Here's who qualifies, what the numbers mean, and what comes next.
Tirzepatide and Intermittent Fasting: Synergy or Sabotage?
Combining tirzepatide with 16:8 intermittent fasting raises real questions about hypoglycemia risk, appetite overlap, and muscle loss. What the evidence shows.
Retatrutide Beyond Weight: Lipids, BP, and Liver Markers
Retatrutide's Phase 2 data shows meaningful shifts in cholesterol, blood pressure, and liver enzymes — here's what the cardiometabolic evidence says.
Semaglutide After Bariatric Surgery: Combine, Replace, or Skip?
Weight regain after bariatric surgery is common. Here's what the evidence says about using semaglutide post-bypass or post-sleeve — and what insurers typically demand.
Tirzepatide and Alcohol Cravings: Emerging Evidence
People on tirzepatide report drinking less. Here's what the early data, the mechanistic plausibility, and the addiction-medicine view all say.
Tirzepatide and Sleep Apnea: SURMOUNT-OSA in Plain English
The SURMOUNT-OSA trials showed tirzepatide dramatically cut AHI scores in adults with obesity and OSA. Here's what the data means for you.
Why Retatrutide Loses More Weight: A Mechanistic Walk-Through
Retatrutide's triple-agonist mechanism targets GLP-1, GIP, and glucagon receptors. Here's why the glucagon component creates a distinctly different weight-loss profile.
What Retatrutide Will Probably Cost: Lessons from Launch
Retatrutide cost prediction using Ozempic, Wegovy, and Zepbound launch data. What payer dynamics, list price anchors, and access patterns to expect.
Where Retatrutide Fits in the GLP-1 Drug Tree
Retatrutide drug class explained: a visual taxonomy from exenatide to liraglutide to semaglutide to tirzepatide to retatrutide. How the incretin drug tree grew.
Semaglutide's Effect on LDL, Triglycerides, and ApoB
Semaglutide cholesterol effects from STEP trial data: LDL, triglycerides, HDL, and ApoB changes. Which effects are drug-direct vs. weight-loss-mediated?
Semaglutide Reflux: Why It Happens and the Food Strategy
Semaglutide reflux is driven by LES relaxation and delayed gastric emptying. How to manage Ozempic heartburn with food choices before reaching for a PPI.
Stepping Down a Tirzepatide Dose: When and Why People Do It
Stepping down tirzepatide makes sense for persistent side effects or maintenance. When dose reduction works, what to expect, and how to avoid regain.
Retatrutide vs Bariatric Surgery: Closing the Gap?
Retatrutide's Phase 2 results showed ~24% weight loss vs surgery's 28–30%. Here's what the gap means and why reversibility changes the calculus.
Semaglutide and Hypothyroidism: Levothyroxine Timing
Semaglutide slows gastric emptying, which can disrupt levothyroxine absorption. Here's the spacing strategy that prevents TSH fluctuations.
Semaglutide and Blood Pressure: What Patients Should Expect
Semaglutide lowers systolic blood pressure 4–6 mmHg on average. Here's what drives that drop and when to adjust your antihypertensives.
Tirzepatide and Food Noise: What Patients Mean
Tirzepatide quiets 'food noise' — the mental preoccupation with eating — for most users. Here's what drives it and what the weight-loss correlation suggests.
Traveling with Tirzepatide: Cold Chain, TSA, Time Zones
Flying with Mounjaro or Zepbound? Here's what the cold chain actually requires, TSA rules for injectable medications, and how to handle time zone dosing shifts.
Retatrutide Pharmacokinetics: Half-Life, Steady State, and Dosing
Retatrutide's PK profile — half-life around 6 days, steady state at ~4 weeks — compared to weekly semaglutide and tirzepatide. What it means for dosing.
Retatrutide's Weight-Loss Curve: When (or Whether) It Plateaus
At 48 weeks, retatrutide's weight-loss curve hasn't clearly flattened. What the data shows, why it matters, and what extrapolation beyond 48 weeks actually means.
Semaglutide Sulfur Burps: Why They Happen, What Stops Them
Semaglutide slows gastric emptying, letting sulfur-containing foods ferment. Here's why the rotten-egg burps happen and what actually stops them.
Tirzepatide Injection Pain: Distribution and Rotation
Why tirzepatide stings on injection, how the three injection sites compare, and the rotation protocol that prevents lipohypertrophy over months of weekly shots.
Tirzepatide for Liver Fat (MASLD/NASH): The SYNERGY-NASH Story
SYNERGY-NASH showed tirzepatide resolving NASH in over half of patients at 52 weeks. Here's what the trial actually measured, and the fibrosis caveat.
Compounded Retatrutide in 2026: Legal Status and Safety
Retatrutide isn't FDA-approved, which creates a murkier legal situation for compounding than semaglutide or tirzepatide. Here's what the 503A/503B rules mean.
Retatrutide vs Semaglutide: What the Math Predicts
Phase 2 data puts retatrutide at ~24% weight loss vs semaglutide's ~15%. Here's what the mechanism gap actually explains — and what it doesn't.
The SELECT Trial in Plain English: Heart Benefit Without Diabetes
SELECT showed semaglutide cut MACE by 20% in people with heart disease but no diabetes. What the trial found, what it means, and what it doesn't prove.
Semaglutide After 65: Dosing, Sarcopenia, and Polypharmacy
GLP-1s work in older adults, but fall risk, muscle loss, dehydration, and drug interactions require a different conversation than for younger patients.
Tirzepatide and Pregnancy Planning: Washout Timeline
Tirzepatide's FDA label requires stopping at least 1 month before conception. Here's what drives that timeline and what alternatives exist during pregnancy.
Semaglutide for BMI 27-30: Eligibility and Outcomes
Wegovy is approved for BMI 27 with one qualifying comorbidity. What the eligibility rules mean, what STEP-1 shows, and realistic outcomes at this range.
Preserving Muscle on Semaglutide: Protein and Sarcopenia
Semaglutide-driven weight loss takes lean mass with it. Here's what DEXA data shows, what protein targets help, and how resistance training protects muscle.
Tirzepatide and Mood: Anxiety and Low Mood Reports Examined
Mood changes and low mood reports appear in tirzepatide FAERS data. Here's what the clinical trial AEs show and why the appetite-pleasure pathway matters.
Tirzepatide and Visceral Fat: What the MRI Studies Actually Found
SURMOUNT body composition substudies used DEXA and MRI to track fat loss on tirzepatide. Here's what the imaging data shows about visceral fat and lean mass.
TRIUMPH-2 vs TRIUMPH-3: Diabetes vs Obesity Arms
Retatrutide's Phase 3 TRIUMPH program splits into diabetes and obesity arms. Here's how TRIUMPH-2 and TRIUMPH-3 differ and what each readout will tell us.
Retatrutide FDA Approval Timeline: What's Realistic
The regulatory math behind retatrutide FDA approval: Phase 3 timelines, NDA submission windows, and brand-name logistics—when can you actually get it?
Retatrutide's Glucagon Paradox: Why Adding It Helps
Glucagon normally raises blood sugar—so why does retatrutide add glucagon agonism? The pharmacology that may give retatrutide its edge over tirzepatide.
Semaglutide and HbA1c: Trajectories at 3, 6, 12 Months
The SUSTAIN trial curve for semaglutide A1c reduction: how much falls at 3, 6, and 12 months—and when your prescriber should consider adding a second agent.
Tirzepatide for Prediabetes: Off-Label and Insurance
SURMOUNT-1 showed tirzepatide reversed prediabetes in most participants. Here's what that means for off-label use and how insurance actually handles it.
Tirzepatide Step-Up Decisions: When to Move Up, When to Hold
A practical guide to tirzepatide step-up decisions: the tolerance signals that mean wait, the plateau signals that mean move, and the hard stops.
Retatrutide vs Tirzepatide: Efficacy and Tolerability
Retatrutide vs tirzepatide: how to compare a triple and dual agonist across trials that weren't designed to compete. Efficacy, tolerability, and key caveats.
Semaglutide and Gallbladder Risk: What to Watch For
Semaglutide and gallbladder disease: what the STEP-1 data showed, why rapid weight loss triggers cholesterol stones, and the warning signs to watch for.
Semaglutide vs Saxenda: When Daily Injections Make Sense
Semaglutide vs Saxenda: frequency, washout, and formulary coverage compared. When liraglutide's short half-life gives it a real edge over weekly semaglutide.
Tirzepatide Hair Shedding: Telogen Effluvium Pattern and Timeline
Tirzepatide hair loss follows the telogen effluvium pattern — triggered by rapid weight loss, not the drug itself. Timeline, labs to run, and what helps.
TRIUMPH-1 Decoded: 24% Weight Loss at 48 Weeks
TRIUMPH-1 delivered ~24% weight loss for retatrutide at 48 weeks. Here's the dose-response breakdown and how it compares to STEP and SURMOUNT data.
The Three-Tier Constipation Protocol for Semaglutide Users
Semaglutide slows your gut. Here's the structured protocol — hydration, soluble fiber, then osmotic laxatives — that most people never get explained to them.
STEP Trial Results Decoded: What 15% Weight Loss Means
The STEP trials put semaglutide on the map with a 14.9% weight loss headline. What that number actually means — and why your result may look very different.
The SURPASS Trials Decoded: Tirzepatide for Type 2 Diabetes
The SURPASS program put tirzepatide head-to-head with semaglutide and insulin. Here's what the A1c and weight data actually show — and what it means for treatment.
Tirzepatide Has Six Maintenance Doses: How to Pick Yours
Tirzepatide offers six dose levels from 2.5 to 15 mg. Understanding the differences — and how to choose a maintenance dose — changes how you think about the drug.
Retatrutide Explained: What a Triple Agonist Actually Does
Retatrutide targets GIP, GLP-1, and glucagon receptors simultaneously. Here's why adding glucagon to the mix changes the mechanism — and what early trials found.
Why the 0.25 mg Semaglutide Starter Dose Isn't Useless
Most people think the semaglutide 0.25 mg starter dose is too low to matter. The pharmacology disagrees. Here's what's happening in those first four weeks.
Semaglutide Cycling: Continuous Use vs Planned Breaks
Semaglutide cycling — taking planned breaks from the drug — sounds like a hedge against tolerance and side effects. The human evidence is thinner than you'd hope.
Stretching Semaglutide to Every 9 or 10 Days: What the PK Allows
Can you take semaglutide every 9 days instead of weekly? The pharmacokinetics give a real answer — with two specific scenarios where stretching breaks down.
Semaglutide Split Dose: What Pharmacokinetics Actually Say
A semaglutide split dose sounds smart in theory — twice-weekly half doses to smooth side effects. The pharmacokinetics tell a quieter story. Here's the math.
Morning vs Evening Semaglutide: The Half-Life Math
When to inject semaglutide is one of the most-asked questions — and most timing rules online don't survive the half-life math. Here's what actually matters.
GLP-1 and Exercise: Why Workouts Feel Different
Workouts feel different on a GLP-1. Here's what changes — energy, fuel, muscle — and how to train so the weight you lose isn't mostly muscle.
GLP-1 for PCOS: What the Early Data Shows
GLP-1s like Ozempic and Mounjaro are being used off-label for PCOS. What the evidence actually shows on weight, cycles, fertility, and insulin resistance.
GLP-1 Microdosing: What the Evidence Actually Says
GLP-1 microdosing is everywhere on social media. The clinical evidence is thinner than the trend. Here's what trial data and pharmacology actually support.
How GLP-1s Affect Sleep: Insomnia, Dreams, and Apnea
GLP-1s wreck sleep in week one and rescue it by month six. Here's what insomnia, vivid dreams, and sleep apnea look like on semaglutide and tirzepatide.
Why Your GLP-1 Weight Loss Plateaued (And What to Try)
Plateaus on Ozempic, Wegovy, or Zepbound are normal — and almost always solvable. Here's what causes them and the playbook that actually works.
What to Eat on GLP-1s When You Have No Appetite
Your appetite is gone but your body still needs protein, fiber, and nutrients. The eating playbook for Ozempic, Wegovy, and Zepbound users.
What Are GLP-1 Peptides? A Plain-English Guide
GLP-1 peptides like semaglutide and tirzepatide are reshaping weight loss and metabolic health. What they are, how they work, and what to know before starting.